We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
- Authors
Sablerolles, Roos S. G.; Goorhuis, Abraham; GeurtsvanKessel, Corine H.; de Vries, Rory D.; Huckriede, Anke L. W.; Koopmans, Marion P. G.; Lafeber, Melvin; Postma, Douwe F.; van Baarle, Debbie; Visser, Leo G.; Dalm, Virgil A. S. H.; Kootstra, Neeltje A.; Rietdijk, Wim J. R.; van der Kuy, P. Hugo M.
- Abstract
The prime and boost vaccines are administered in a so-called "homologous" vaccination regimen, meaning that both given vaccinations are identical. SARS-CoV-2, COVID-19, randomized clinical trial, Ad26.Cov2.S, BNT162.b2, mRNA1273, Homologous vaccination regimen, Heterologous vaccine regimen Keywords: SARS-CoV-2; COVID-19; Homologous vaccination regimen; Heterologous vaccine regimen; randomized clinical trial; Ad26.Cov2.S; BNT162.b2; mRNA1273 EN SARS-CoV-2 COVID-19 Homologous vaccination regimen Heterologous vaccine regimen randomized clinical trial Ad26.Cov2.S BNT162.b2 mRNA1273 1 4 4 09/29/21 20210924 NES 210924 Currently, four COVID-19 vaccines are authorized for use in the European Union by the European Medicines Agency (EMA), i.e., Ad26.COV2.S ([1]), ChAdOx1 nCoV-19 ([2]), mRNA1273 ([3]), and BNT162b2 ([4]).
- Subjects
COVID-19 vaccines; MEDICAL personnel; BOOSTER vaccines; COVID-19
- Publication
Frontiers in Immunology, 2021, Vol 12, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2021.753319